At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,151 enrolled
Drug / intervention
Effexor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs & Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted May 17, 2007·Updated Mar 5, 2012
In Brief
A Phase 4 clinical trial evaluating Effexor and SSRI for Major Depressive Disorder. Completed, enrolled 1,151 participants across 26 sites.
Detailed Summary
This study is an open-label, randomized, multi-center study conducted in a typical psychiatric outpatient practice in China. This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus SSRIs and conventional antidepressants in depressed patients that previously failed antidepressant treatment. This data will be used to guide psychiatrists on recommendations for clinic use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionMar 2008
TodayJul 2026
First PostedMay 17, 2007
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.1 years ago
Interventions
Effexordrug
SSRIdrug